| Dr Thurman C Morgan Jr, DDS | |
|
2314 Weymouth Dr, Ste A, Baton Rouge, LA 70809-1424 | |
| (225) 926-5138 | |
| (225) 926-7116 |
| Full Name | Dr Thurman C Morgan Jr |
|---|---|
| Gender | Male |
| Speciality | Dentist - Pediatric Dentistry |
| Location | 2314 Weymouth Dr, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255336038 | NPI | - | NPPES |
| 1821446 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223P0221X | Dentist - Pediatric Dentistry | 2144 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thurman C Morgan Jr, DDS 2314 Weymouth Dr, Ste A, Baton Rouge, LA 70809-1424 Ph: (225) 926-5138 | Dr Thurman C Morgan Jr, DDS 2314 Weymouth Dr, Ste A, Baton Rouge, LA 70809-1424 Ph: (225) 926-5138 |
News Archive
Buffalo (N.Y.) News: "Two of the region's three dominant health insurers intend to raise premiums on average by double digits for next year, and the third wants a double-digit increase for plans not structured as health maintenance organizations. The premium for one insurance plan could rise almost 36 percent. The insurers cite rising costs of medical care and federal health care reforms." The increases must be approved by the state (Epstein, 10/10).
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."
› Verified 5 days ago
Dr. Rachel Elizabeth Dier, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 12045 Coursey Blvd, Baton Rouge, LA 70816 Phone: 225-292-8789 | |
Dr. Hoang Van Tran, DDS Dentist Medicare: Medicare Enrolled Practice Location: 10914 Old Hammond Hwy, Baton Rouge, LA 70816 Phone: 225-615-7334 Fax: 225-615-7986 | |
Dr. Michael E Hiller, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 4607 Sherwood Common Blvd, Baton Rouge, LA 70816 Phone: 225-924-7367 Fax: 225-929-9506 | |
Dr. Billy George Hall Jr., D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 5151 Plank Rd, Suite 28, Baton Rouge, LA 70805 Phone: 225-330-6688 Fax: 225-356-8163 | |
Dr. Jana Elaine Boyd, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 11930 S Harrells Ferry Rd, Baton Rouge, LA 70816 Phone: 225-928-5920 | |
James M Hayden, DDS Dentist Medicare: Medicare Enrolled Practice Location: 8160 Ymca Plaza Dr, Suite B, Baton Rouge, LA 70810 Phone: 225-768-8200 Fax: 225-768-8070 | |
Dr. Kredenna Beverly, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2314 Weymouth Dr., Ste. B, Baton Rouge, LA 70809 Phone: 225-926-4444 Fax: 225-926-4050 |